Kirkland advised GTCR and its portfolio company, Maravai LifeSciences Holdings Inc., in connection with Maravai’s $1.6 billion initial public offering, which closed on November 24, 2020. Maravai, a global provider of life science reagents and services, has developed groundbreaking CleanCap technology that is used in producing Pfizer’s COVID-19 vaccine. The Maravai IPO was the second largest healthcare IPO and the sixth largest IPO across all sectors in 2020. Maravai’s Class A common stock began trading on Nasdaq under the ticker symbol “MRVI” on November 20.
The team was led by capital markets partners Bob Hayward, Bob Goedert and Michael Keeley and associates Eileen Kelly, Katie White and Puja Narain, corporate partners Sandy Perl, Michael Weed and Daniel Guerin, and associates Jake Flood and Chris Grady, debt finance partners Jocelyn Hirsch, Tom Dobleman and Kyle Gillen and associate Emily Hogan, tax partners Polina Liberman, Gregory Gallagher and associate Mohsen Ghazi, and executive compensation partners Stephen Jacobson, Stephanie Jeane and associate David Branham.